NCT00258284 - Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer | Biotech Hunter

Enrollment

30

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Prostate Cancer

Interventions

DRUG

capecitabine

Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR

DRUG

docetaxel

Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR

Trial Locations (1)

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit